Evaluation of Antigenic Differences Between Wild and Sabin Vaccine Strains of Poliovirus Using the Pseudovirus Neutralization Test

Overview

Journal Sci Rep

Specialty Science

Date 2019 Aug 21

PMID 31427704

Citations 6

Authors

Minetaro Arita

Masae Iwai-Itamochi

Affiliations

Soon will be listed here.

Abstract

In the endgame of global polio eradication, serosurveillance is essential to monitor each country's vulnerability to poliomyelitis outbreaks. Previously, we developed pseudovirus poliovirus (PV) neutralization test (pPNT) with type 1, 2, and 3 PV pseudovirus (PV), which possess a luciferase-encoding PV replicon in the capsids of wild-type strains (PV[WT]), showing that pPNT with type 2 and 3 PV(WT) but not type 1 shows high correlation with the conventional PV neutralization test (cPNT) performed with vaccine strains. Here, we analyse the antigenicity of PV(WT) and PV with capsid proteins of Sabin vaccine strains (PV[Sabin]) in human serum. Type 2 and 3 PV(WT) and PV(Sabin) show similar antigenicity in the analysed set of human sera in contrast to type 1 PV. The levels of PV(Sabin) infection (%), including about 70% of PV infection (%) measured in the presence of human serum diluted to the cPNT titre, serve as the optimal threshold values for pPNT (5% for type 1 and 2, 10% for type 3) to show high correlation with cPNT results. Our results suggest that pPNT with PV(Sabin) could serve as an alternative to cPNT and provide a rationale for pPNT threshold values.

Citing Articles

Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient.

Wu Y, Zhang R, Yuan G, He L, Dai X, Chuan H Viruses. 2024; 16(11).

PMID: 39599874 PMC: 11598955. DOI: 10.3390/v16111761.

An efficient complementation system for replication of defective poliovirus mutants.

Arita M J Virol. 2024; 98(7):e0052324.

PMID: 38837378 PMC: 11265389. DOI: 10.1128/jvi.00523-24.

Pseudotyped Viruses for Enterovirus.

Wu X, Cui L, Bai Y, Bian L, Liang Z Adv Exp Med Biol. 2023; 1407:209-228.

PMID: 36920699 DOI: 10.1007/978-981-99-0113-5_11.

Pseudotyped Viruses.

Wang Y, Zhou Z, Wu X, Li T, Wu J, Cai M Adv Exp Med Biol. 2023; 1407:1-27.

PMID: 36920689 DOI: 10.1007/978-981-99-0113-5_1.

High-throughput analysis of anti-poliovirus neutralization antibody titre in human serum by the pseudovirus neutralization test.

Arita M, Iwai-Itamochi M Sci Rep. 2022; 12(1):16074.

PMID: 36167892 PMC: 9514167. DOI: 10.1038/s41598-022-20544-6.

References

Blondel B, Crainic R, Fichot O, Dufraisse G, Candrea A, Diamond D . Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J Virol. 1986; 57(1):81-90. PMC: 252701. DOI: 10.1128/JVI.57.1.81-90.1986. View

Wright E, Temperton N, Marston D, McElhinney L, Fooks A, Weiss R . Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol. 2008; 89(Pt 9):2204-2213. PMC: 2886951. DOI: 10.1099/vir.0.2008/000349-0. View

Rimoin A, Lu K, Bramble M, Steffen I, Doshi R, Hoff N . Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection. J Infect Dis. 2017; 217(2):223-231. PMC: 5853670. DOI: 10.1093/infdis/jix584. View

Brickley E, Strauch C, Wieland-Alter W, Connor R, Lin S, Weiner J . Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. J Infect Dis. 2018; 217(3):371-380. PMC: 5853416. DOI: 10.1093/infdis/jix556. View

Arita M, Nagata N, Sata T, Miyamura T, Shimizu H . Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J Gen Virol. 2006; 87(Pt 11):3317-3327. DOI: 10.1099/vir.0.82172-0. View

Arita M, Bigay J . Poliovirus Evolution toward Independence from the Phosphatidylinositol-4 Kinase III β/Oxysterol-Binding Protein Family I Pathway. ACS Infect Dis. 2019; 5(6):962-973. DOI: 10.1021/acsinfecdis.9b00038. View

Arita M, Iwai M, Wakita T, Shimizu H . Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum. Clin Vaccine Immunol. 2011; 18(11):1889-94. PMC: 3209023. DOI: 10.1128/CVI.05225-11. View

Han D, Kim H, Kim Y, Poon L, Cho M . Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology. 2004; 326(1):140-9. PMC: 7127165. DOI: 10.1016/j.virol.2004.05.017. View

Iwai M, Takizawa T, Nakayama T, Matsuura K, Yoshida H, Hasegawa S . Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. Scand J Infect Dis. 2007; 40(3):247-53. DOI: 10.1080/00365540701596003. View

10.

Hotta C, Ogawa T, Shirasawa H . Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine. Hum Vaccin Immunother. 2019; 15(5):1154-1159. PMC: 6605838. DOI: 10.1080/21645515.2019.1572408. View

11.

Shimizu H . Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2014; 34(16):1975-85. DOI: 10.1016/j.vaccine.2014.11.015. View

12.

Tamin A, Harcourt B, Lo M, Roth J, Wolf M, Lee B . Development of a neutralization assay for Nipah virus using pseudotype particles. J Virol Methods. 2009; 160(1-2):1-6. PMC: 2704486. DOI: 10.1016/j.jviromet.2009.02.025. View

13.

Jiang Z, Liu G, Guo-Yang L, Sun M, Xu K, Ying Z . A simple and safe antibody neutralization assay based on polio pseudoviruses. Hum Vaccin Immunother. 2018; 15(2):349-357. PMC: 6422504. DOI: 10.1080/21645515.2018.1526553. View

14.

Couderc T, Christodoulou C, KOPECKA H, Marsden S, Taffs L, Crainic R . Molecular pathogenesis of neural lesions induced by poliovirus type 1. J Gen Virol. 1989; 70 ( Pt 11):2907-18. DOI: 10.1099/0022-1317-70-11-2907. View

15.

Resik S, Tejeda A, Fonseca M, Sein C, Hung L, Martinez Y . Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies. Trials Vaccinol. 2016; 4:71-74. PMC: 4802416. DOI: 10.1016/j.trivac.2015.08.001. View

16.

Fukushi S, Mizutani T, Saijo M, Kurane I, Taguchi F, Tashiro M . Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J Med Virol. 2006; 78(12):1509-12. PMC: 7166816. DOI: 10.1002/jmv.20732. View

17.

Liu S, Song D, Bai H, Lu W, Dai X, Hao C . A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus. J Med Virol. 2017; 89(12):2075-2083. DOI: 10.1002/jmv.24909. View

18.

Wang W, Butler E, Veguilla V, Vassell R, Thomas J, Moos Jr M . Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods. 2008; 153(2):111-9. DOI: 10.1016/j.jviromet.2008.07.015. View

19.

BODIAN D . Viremia in experimental poliomyelitis. I. General aspects of infection after intravascular inoculation with strains of high and of low invasiveness. Am J Hyg. 1954; 60(3):339-57. View

20.

Nakayama T, Suga S, Okada K, Okabe N . Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV). Jpn J Infect Dis. 2018; 72(1):49-52. DOI: 10.7883/yoken.JJID.2018.314. View